New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...

Munich, December 18, 2013 - Sandoz announced today that it has received Danish marketing authorization for AirFluSal ® Forspiro ®, an innovative new inhaler for patients with asthma and/or chronic ...

Vectura, the AIM-listed respiratory development company, confirmed that its partner Sandoz, has received Swedish marketing authorisation for AirFluSal Forspiro, a new inhaler for patients with asthma ...

(Reuters) - Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court ...

LONDON (Alliance News) - Vectura Group PLC on Wednesday said its partner has announced the launch of the AirFluSal Forspiro inhaler in Portugal and Ireland. Vectura said the confirmation of the launch ...

Sandoz has launched in the UK a new patient-centric inhaler for the symptomatic treatment of chronic obstructive pulmonary disease. Sandoz has launched in the UK a new patient-centric inhaler for the ...

LONDON—GlaxoSmithKline PLC has scored a minor victory in the battle to keep sales of its $9 billion-a-year asthma treatment Advair from being lost to generic competitors. The company has obtained a ...

A major pharmaceutical company has claimed alleged infringement of its trademark entitles it to an injunction preventing the roll-out by a rival of an inhaler for asthmatics. GlaxoSmithKline (GSK) ...

Not enough drugmakers on the “smart inhaler” bandwagon for you? Well, go ahead and add AstraZeneca to the list. The British pharma giant is teaming up with Quintiles on a clinical trial to test ...

Novel inhaler approved for patients with asthma and COPD Approval follows completion of EU decentralized procedure (DCP) AirFluSal® Forspiro® strengthens Sandoz respiratory portfolio and reinforces ...

Munich, December 18, 2013 - Sandoz announced today that it has received Danish marketing authorization for AirFluSal ® Forspiro ®, an innovative new inhaler for patients with asthma and/or chronic ...